Effects of lactoferrin on dexamethasone-induced osteoporosis in mice

Izumo, Nobuo; Kagaya, Shinji; Toho, Masahiro; Furukawa, Megumi; Kabaya, Yasuka; Hanabusa, Takao; Hayamizu, Kohsuke; Nakano, Makoto; Hoshino, Tatsuo; Watanabe, Yasuo

doi:10.15761/gdt.1000149

Cited by 2 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, osterix regulates osteocalcin involvement in calcification [ 24 ]. These results, supported previous studies which bovine LF improved osteogenic marker genes in vivo and in vitro, suggest that LF-II can affect osterix expression and enhance calcification after 2–8 h, demonstrating that human recombinant LF has similar effects as bovine LF [ 11 , 12 , 13 , 17 ].…”

Section: Discussionsupporting

confidence: 89%

“…MC3T3-E1 cells were seeded at a density of 1 × 10 4 cells/well in 96-well plates and cultured in α-MEM supplemented with 10% FBS. After incubation for 1 d, the growth medium was changed to include 100 μg/mL LF (IF-I and LF-II) with or without 50 μg/mL ascorbic acid and 10 mM β-glycerophosphate (β-GP), then incubated for 24 h. Concentration of LF were determined according to previous studies [ 17 ]. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed using a CellQuanti-MTT cell viability assay kit (BioAssay Systems, CA, USA), and absorbance was measured at 570 nm.…”

Section: Methodsmentioning

confidence: 99%

“…Finally, mature osteoblasts are embedded in the calcified bone matrix. Recent data suggest that LF promotes osteoblast proliferation and inhibits bone resorption through acting on osteoclasts [ 16 , 17 ]. Previous studies in steroid-induced osteopenic mice have also reported that LF significantly improves bone quantity [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Human Recombinant Lactoferrin Promotes Differentiation and Calcification on MC3T3-E1 Cells

et al. 2022

View full text Add to dashboard Cite

Lactoferrin (LF), known to be present in mammalian milk, has been reported to promote the proliferation of osteoblasts and suppress bone resorption by affecting osteoclasts. However, the mechanisms underlying the effects of human sources LF on osteoblast differentiation have not yet been elucidated, and almost studies have used LF from bovine sources. The presented study aimed to characterize the molecular mechanisms of bovine lactoferrin (IF-I) and human recombinant lactoferrin (LF-II) on MC3T3-E1 pre-osteoblast cells. MC3T3-E1 cells were treated with LF, ascorbic acid, and β-glycerophosphate (β-GP). Cell proliferation was analyzed using the MTT assay. Alkaline phosphatase activation and osteopontin expression levels were evaluated via cell staining and immunocytochemistry. The differentiation markers were examined using quantitative real-time PCR. The cell viability assay showed the treatment of 100 μg/mL LF significantly increased; however, it was suppressed by the simultaneous treatment of ascorbic acid and β-GP. Alizarin red staining showed that the 100 μg/mL treatment of LF enhanced calcification. Quantitative real-time PCR showed a significant increase in osterix expression. The results suggest that treatment with both LFs enhanced MC3T3-E1 cell differentiation and promoted calcification. The mechanisms of calcification suggest that LFs are affected by an increase in osterix and osteocalcin mRNA levels.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Human Recombinant Lactoferrin Promotes Differentiation and Calcification on MC3T3-E1 Cells

et al. 2022

View full text Add to dashboard Cite

show abstract

“…After oral administration for the first 2 weeks, all mice were intraperitoneally injected with DEX (15 mg/kg/day). Many studies have reported that 2 weeks to 1 month of DEX treatment results in muscle atrophy or bone loss in mice and rats [ [29] , [30] , [31] , [32] , [33] , [34] , [35] ]. We induced both muscle atrophy and bone loss by intraperitoneally injecting DEX for 1 month.…”

Section: Methodsmentioning

confidence: 99%